Published in FEBS Lett on November 13, 1995
CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol (2010) 2.74
CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A (2005) 2.36
Brain cannabinoid CB₂ receptors modulate cocaine's actions in mice. Nat Neurosci (2011) 1.88
Cannabinoids and neuroinflammation. Br J Pharmacol (2004) 1.62
CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin. J Biol Chem (2010) 1.47
Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med (2009) 1.44
Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. Genes Brain Behav (2009) 1.29
Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands. Mol Pharmacol (2011) 1.15
Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: antinociceptive actions of CB1 inverse agonists. J Neurosci (2008) 1.10
A review of the interactions between alcohol and the endocannabinoid system: implications for alcohol dependence and future directions for research. Alcohol (2012) 1.02
Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. Biochem J (2002) 0.99
Endocannabinoids suppress excitatory synaptic transmission to dorsal raphe serotonin neurons through the activation of presynaptic CB1 receptors. J Pharmacol Exp Ther (2009) 0.98
Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. Br J Pharmacol (2005) 0.95
Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. Endocr Metab Immune Disord Drug Targets (2008) 0.92
Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br J Pharmacol (2011) 0.91
AM2389, a high-affinity, in vivo potent CB1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice. Psychopharmacology (Berl) (2011) 0.88
hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation. Chem Biol (2010) 0.87
The extracellular regulated kinases (ERK) 1/2 mediate cannabinoid-induced inhibition of gap junctional communication in endothelial cells. Br J Pharmacol (2002) 0.83
Structural determinants in the second intracellular loop of the human cannabinoid CB1 receptor mediate selective coupling to G(s) and G(i). Br J Pharmacol (2010) 0.83
Mistic and TarCF as fusion protein partners for functional expression of the cannabinoid receptor 2 in Escherichia coli. Protein Expr Purif (2012) 0.82
What we know and do not know about the cannabinoid receptor 2 (CB2). Semin Immunol (2014) 0.81
Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. Brain Struct Funct (2014) 0.81
Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway. J Pharmacol Exp Ther (2016) 0.80
The CB2 receptor and its role as a regulator of inflammation. Cell Mol Life Sci (2016) 0.79
2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces rapid actin polymerization in HL-60 cells differentiated into macrophage-like cells. Biochem J (2005) 0.77
Sch35966 is a potent, selective agonist at the peripheral cannabinoid receptor (CB2) in rodents and primates. Br J Pharmacol (2007) 0.77
Brain innate immunity in the regulation of neuroinflammation: therapeutic strategies by modulating CD200-CD200R interaction involve the cannabinoid system. Curr Pharm Des (2014) 0.75
Interactions of Cannabinoids With Biochemical Substrates. Subst Abuse (2017) 0.75
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 16.31
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
Two populations of Ia-like molecules on a human B cell line. J Immunol (1980) 7.68
The genome of the natural genetic engineer Agrobacterium tumefaciens C58. Science (2001) 6.90
'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns. Genome Biol (2000) 5.29
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 4.97
Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med (1993) 4.91
IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol (1997) 4.32
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med (1996) 4.15
Acetylcholine receptors of muscle grown in vitro. Proc Natl Acad Sci U S A (1972) 3.96
The Lewy-body variant of Alzheimer's disease. Clinical and pathological findings. Br J Psychiatry (1993) 3.95
Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med (1982) 3.78
Studies of a human T lymphocyte antigen recognized by a monoclonal antibody. Proc Natl Acad Sci U S A (1981) 3.63
Obliquity-paced Pliocene West Antarctic ice sheet oscillations. Nature (2009) 3.42
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature (2001) 3.33
Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med (1992) 2.73
Measuring client gains from staff-implemented programs. J Appl Behav Anal (1978) 2.72
Development of acetylcholine receptor clusters on cultured muscle cells. Proc Natl Acad Sci U S A (1973) 2.71
Tacrine in Alzheimer's disease. Lancet (1991) 2.67
Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature (1993) 2.62
TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol (1990) 2.60
Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav (1991) 2.57
The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther (1994) 2.55
Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat Med (2000) 2.55
Detection of T and B cell antigens hybridoma monoclonal antibodies: a biotin-avidin-horseradish peroxidase method. J Histochem Cytochem (1980) 2.52
Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood (1994) 2.48
Complete genome sequence of the genetically tractable hydrogenotrophic methanogen Methanococcus maripaludis. J Bacteriol (2004) 2.47
Prospective study to determine clinical relevance of detection of pneumococcal DNA in sera of children by PCR. J Clin Microbiol (1998) 2.42
Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology (1980) 2.41
The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol (1999) 2.40
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol (2000) 2.38
Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood (2001) 2.35
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A (1999) 2.32
A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease. Brain (1988) 2.32
The neural system that bridges reward and cognition in humans: an fMRI study. Proc Natl Acad Sci U S A (2002) 2.26
Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci U S A (2000) 2.24
Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease. Ann Neurol (1998) 2.21
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol (2001) 2.15
Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. Leukemia (2003) 2.12
Marihuana chemistry. Science (1970) 2.10
Carbon monoxide re-breathing during low-flow anaesthesia in infants and children. Br J Anaesth (2010) 2.09
Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization. Proc Natl Acad Sci U S A (1978) 2.06
Hurthle cell carcinoma of the thyroid gland. A tumor of moderate malignancy. Cancer (1986) 2.04
Psychiatric phenomena in Alzheimer's disease. I: Disorders of thought content. Br J Psychiatry (1990) 2.01
Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem (1997) 2.01
The monoclonality of human B-cell lymphomas. J Exp Med (1977) 1.97
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (2000) 1.96
Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial. Blood (1997) 1.96
Chemical basis of hashish activity. Science (1970) 1.94
A human thymus-leukemia antigen defined by hybridoma monoclonal antibodies. Proc Natl Acad Sci U S A (1979) 1.94
Lewy bodies and response to tacrine in Alzheimer's disease. Lancet (1994) 1.94
The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry (1989) 1.94
Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma. Cell (1986) 1.92
Impaired lymphocyte function in untreated Hodgkin's disease. N Engl J Med (1974) 1.91
Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res (1999) 1.91
A clinical trial of anti-idiotype therapy for B cell malignancy. Blood (1985) 1.91
Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant (1999) 1.90
Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J Infect Dis (1995) 1.88
Complications of intracranial pressure monitoring in fulminant hepatic failure. Lancet (1993) 1.87
2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A (2001) 1.86
Myasthenia gravis: a serum factor blocking acetylcholine receptors of the human neuromuscular junction. Lancet (1975) 1.84
Accuracy of clinical diagnosis of Alzheimer's disease. BMJ (1990) 1.84
Cognitive performance in tests sensitive to frontal lobe dysfunction in the elderly depressed. Psychol Med (1996) 1.84
An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol (1998) 1.83
Clonal evolution of a follicular lymphoma: evidence for antigen selection. Proc Natl Acad Sci U S A (1992) 1.82
The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene (1997) 1.81
Early medical use of cannabis. Nature (1993) 1.80
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood (1982) 1.79
Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines. Cancer (1978) 1.77
Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet (1981) 1.76
Coexpression studies with mutant muscarinic/adrenergic receptors provide evidence for intermolecular "cross-talk" between G-protein-linked receptors. Proc Natl Acad Sci U S A (1993) 1.75
The inference of antigen selection on Ig genes. J Immunol (2000) 1.74
Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol (1993) 1.73
Mouse x human heterohybridomas as fusion partners with human B cell tumors. J Immunol Methods (1986) 1.73
Cytokeratins of normal epithelia and some neoplasms of the female genital tract. Lab Invest (1983) 1.70
Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatremia. Cancer (1977) 1.69
Immunologic phenotype in 30 patients with diffuse large-cell lymphoma. N Engl J Med (1980) 1.68
Computed tomography in the elderly. 2. Senile dementia: diagnosis and functional impairment. Br J Psychiatry (1980) 1.68
Monocyte dysfunction in patients with Gaucher disease: evidence for interference of glucocerebroside with superoxide generation. Blood (1994) 1.68
Microstimulation-induced inhibition of neuronal firing in human globus pallidus. J Neurophysiol (2000) 1.67
A factor from neurons increases the number of acetylcholine receptor aggregates on cultured muscle cells. Proc Natl Acad Sci U S A (1978) 1.66
TAPA-1, the target of an antiproliferative antibody, is associated on the cell surface with the Leu-13 antigen. J Immunol (1990) 1.65
Human T lymphocytes and monocytes bear the same Leu-3(T4) antigen. J Immunol (1986) 1.65
Coupled temporal memories in Parkinson's disease: a dopamine-related dysfunction. J Cogn Neurosci (1998) 1.64
A human X-linked antigen defined by a monoclonal antibody. Somatic Cell Genet (1980) 1.64
Computerised tomography in Alzheimer's disease. Methods of scan analysis, comparison with normal controls, and clinical/radiological associations. Br J Psychiatry (1991) 1.63
Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Mol Immunol (1992) 1.61
Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry (1996) 1.60
Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res (2011) 1.60
Discovery and characterization of endogenous cannabinoids. Life Sci (1999) 1.56
Functional role of proline and tryptophan residues highly conserved among G protein-coupled receptors studied by mutational analysis of the m3 muscarinic receptor. EMBO J (1993) 1.56
Age associated memory impairment. BMJ (1992) 1.54